EGFR and cancer: While many of these trials are ongoing, some ITs are currently approved for CRC including mAbs that target cancer-associated antigens, namely panitumumab (anti-EGFR), cetuximab (anti-EGFR), and bevacizumab (anti-VEGF) [7].